Watch for the definitive agreement deadline (Nov 30, 2026) — failure to execute would nullify the term sheet. Also monitor any FDA regulatory pathway developments for ibogaine, as the entire program is pre-clinical and faces controlled-substance barriers.
Price Chart
Executive Summary
Psyence Biomedical subsidiary Texas Ibogaine Research Corporation (TIRC) signed a binding term sheet with related-party PsyLabs for exclusive U.S. rights to pharmaceutical-grade ibogaine, including license, supply, and wholesale distribution. The deal involves up to ~$1.3M in milestone payments plus royalties, but remains contingent on a definitive agreement by November 30, 2026, and faces significant regulatory hurdles as ibogaine is a controlled substance without FDA approval. The related-party nature and early-stage, pre-clinical status limit near-term impact.
Key Financial Metrics
Key Facts
- TIRC entered a binding term sheet with PsyLabs for exclusive U.S. license, supply, and wholesale distribution of pharmaceutical-grade ibogaine.
- Milestone payments total up to ~$1.3 million for the first drug candidate, plus a low single-digit royalty on net sales and an annual exclusivity fee.
- Definitive agreement must be signed by November 30, 2026, or the term sheet lapses.
- PsyLabs is a significant shareholder of Psyence BioMed and Psyence BioMed holds an ownership interest in PsyLabs — a related-party transaction.
- Ibogaine is a controlled substance; no FDA approval exists, and no clinical trial has been commenced or regulatory application filed.
- TIRC is wholly owned and financed by Psyence BioMed.
Financial Impact
Up to ~$1.3M in milestone payments for first drug candidate; low single-digit royalty on net sales; annual exclusivity fee creditable against royalties. No revenue or cash flow impact in near term.
Risk Factors
- Definitive agreement may not be signed by November 30, 2026, causing the term sheet to lapse.
- Ibogaine is a Schedule I controlled substance; FDA approval is uncertain and years away.
- Related-party transaction may face scrutiny over arm's-length pricing.
- TIRC's exclusivity is conditional on minimum performance thresholds not yet defined.
- Company may need additional financing to fund development milestones.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369752 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $3.66 (−19.03%) |
Oct 15, 2026 11d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $3.66 (−15.28%) |
Oct 5, 2026 21d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 22d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 22d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Sep 28, 2026 29d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 28, 2026 29d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $3.66 (+42.00%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $3.66 (−39.00%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $3.66 (−16.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers